CN117295744A - 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法 - Google Patents

具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法 Download PDF

Info

Publication number
CN117295744A
CN117295744A CN202280035356.1A CN202280035356A CN117295744A CN 117295744 A CN117295744 A CN 117295744A CN 202280035356 A CN202280035356 A CN 202280035356A CN 117295744 A CN117295744 A CN 117295744A
Authority
CN
China
Prior art keywords
formula
compound
compound represented
salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280035356.1A
Other languages
English (en)
Chinese (zh)
Inventor
津村武史
一色聪志
奥江雅之
佐佐木锐郎
节原谦一
毛利伸介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Priority to CN202610020318.9A priority Critical patent/CN121873082A/zh
Publication of CN117295744A publication Critical patent/CN117295744A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Health & Medical Sciences (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
CN202280035356.1A 2021-06-30 2022-06-30 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法 Pending CN117295744A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610020318.9A CN121873082A (zh) 2021-06-30 2022-06-30 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-108230 2021-06-30
JP2021108230 2021-06-30
PCT/JP2022/026168 WO2023277120A1 (ja) 2021-06-30 2022-06-30 二環性ピペラジン環を有するベンゾオキサゾール誘導体又はその塩の製造方法、並びに、その原料の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610020318.9A Division CN121873082A (zh) 2021-06-30 2022-06-30 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法

Publications (1)

Publication Number Publication Date
CN117295744A true CN117295744A (zh) 2023-12-26

Family

ID=84691891

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280035356.1A Pending CN117295744A (zh) 2021-06-30 2022-06-30 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法
CN202610020318.9A Pending CN121873082A (zh) 2021-06-30 2022-06-30 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610020318.9A Pending CN121873082A (zh) 2021-06-30 2022-06-30 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法

Country Status (12)

Country Link
US (1) US20240309010A1 (https=)
EP (1) EP4365174A4 (https=)
JP (2) JP7476431B2 (https=)
KR (1) KR20240027603A (https=)
CN (2) CN117295744A (https=)
AR (1) AR126290A1 (https=)
AU (1) AU2022300611A1 (https=)
BR (1) BR112023025934A2 (https=)
CA (1) CA3223354A1 (https=)
IL (1) IL309736A (https=)
MX (1) MX2023014123A (https=)
WO (1) WO2023277120A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005429A1 (ja) * 2013-07-10 2015-01-15 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
CN110114358A (zh) * 2016-12-26 2019-08-09 明治制果药业株式会社 新的化合物以及其药理学上所容许的盐
WO2020004518A1 (ja) * 2018-06-27 2020-01-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
WO2020004521A1 (ja) * 2018-06-27 2020-01-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005429A1 (ja) * 2013-07-10 2015-01-15 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
CN110114358A (zh) * 2016-12-26 2019-08-09 明治制果药业株式会社 新的化合物以及其药理学上所容许的盐
WO2020004518A1 (ja) * 2018-06-27 2020-01-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
WO2020004521A1 (ja) * 2018-06-27 2020-01-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 炎症性疾患、自己免疫疾患、線維化疾患、及びがん疾患の治療剤

Also Published As

Publication number Publication date
JPWO2023277120A1 (https=) 2023-01-05
IL309736A (en) 2024-02-01
WO2023277120A1 (ja) 2023-01-05
JP2024096941A (ja) 2024-07-17
AU2022300611A1 (en) 2024-01-25
MX2023014123A (es) 2023-12-12
CN121873082A (zh) 2026-04-17
JP7476431B2 (ja) 2024-04-30
CA3223354A1 (en) 2023-01-05
JP7839217B2 (ja) 2026-04-01
EP4365174A1 (en) 2024-05-08
TW202311242A (zh) 2023-03-16
AR126290A1 (es) 2023-10-04
EP4365174A4 (en) 2025-07-02
KR20240027603A (ko) 2024-03-04
US20240309010A1 (en) 2024-09-19
BR112023025934A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
AU2019222559B2 (en) Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
KR102396059B1 (ko) 신규 화합물 및 이의 제조방법
KR102230628B1 (ko) 보르티옥세틴 제조 방법
CN111620849B (zh) 制备二芳基硫代乙内酰脲化合物的方法
KR20120084622A (ko) 시타글립틴의 중간체 제조방법
CN113767094B (zh) 3-甲基-1,2,4-噻二唑-5-碳酰肼及其甲基-d3氘代形式的合成
CN111295381A (zh) 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法
TW201213297A (en) Production method of intermediate compound for synthesizing medicament
CN113039178A (zh) 吡啶并[2,3-d]嘧啶-7(8H)-酮的合成
KR20170122807A (ko) 피리미딘 유도체 및 그의 중간체를 제조하기 위한 화학적 방법
CN102015625B (zh) 取代联苯胺的制备方法
CN101133016A (zh) 制备取代联苯的方法
JPH0578305A (ja) ビグアニド誘導体の製造方法
CN117295744A (zh) 具有二环性哌嗪环的苯并噁唑衍生物或其盐的制造方法以及其原料的制造方法
CN103664816B (zh) Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
RU2858377C2 (ru) Способ получения производного бензоксазола, содержащего бициклическое пиперазиновое кольцо, или его соли и способ получения исходного вещества для него
CN110831944A (zh) 通过极有效制备中间体2,4,5-三氟苯乙酸来制备西他列汀的有效方法
TWI915570B (zh) 具有二環性哌嗪環之苯并噁唑衍生物或其鹽之製造方法以及其原料之製造方法
CZ301697A3 (cs) Způsob přípravy 2-substituovaných benzo/b/thiofenových sloučenin a jeho meziprodukty
CN101374799A (zh) 制备取代联苯的方法
JP6616244B2 (ja) 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
US20130137889A1 (en) Strecker reagents, their derivatives, methods for forming the same and improved strecker reaction
TW202613125A (zh) 具有二環性哌嗪環之苯并噁唑衍生物或其鹽之製造方法以及其原料之製造方法
WO2006124283A1 (en) Bis-amination of aryl halides
CN107635959A (zh) 氨基甲酸酯化合物的制造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination